Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives – an approach to specifying rates

Samuelsson, Eva; Hedenmalm, Karin; Persson, Ingemar

doi:10.1007/s10654-005-4266-7

Cited by 23 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 A controversially discussed risk factor is the use of oral contraceptives (OCs). [9][10][11][12] There are several puzzling observations about OCs and DVT awaiting explanation. The highest risk is found in the first year of use; it falls more than 50% in the following period and disappears after discontinuation of the drug.…”

mentioning

confidence: 99%

Risk Factors for Deep Vein Thrombosis in Women Aged 18 to 50: A Retrospective Analysis

Binder

Lackner

Salmhofer

et al. 2009

Dermatologic Surgery

View full text Add to dashboard Cite

In our patient group, the most important risk factors were older age and immobilization. DVT is typically idiopathic and may be caused by subtle nondetectable thrombophilic disorders. The use of OCs was distributed in DVT patients just as in the general Austrian community and seems not to be a severe additional risk factor. Examining the whole lower extremity during ultrasonography is important so as not to overlook a DVT of the lower leg.

show abstract

mentioning

confidence: 99%

Risk Factors for Deep Vein Thrombosis in Women Aged 18 to 50: A Retrospective Analysis

Binder

Lackner

Salmhofer

et al. 2009

Dermatologic Surgery

View full text Add to dashboard Cite

show abstract

“…A second potential source of bias in this retrospective case-control study is that we could recruit only survivors of VTE. However, given that the fatality rate associated with VTE in women of fertile age is about 1%, 36 this cannot have a substantial effect on the risk estimates.…”

Section: Discussionmentioning

confidence: 99%

Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study

Dinger

Aßmann

Möhner

et al. 2010

j fam plann reprod health care

View full text Add to dashboard Cite

Objective The primary objective of the study was to clarify whether the use of the oral contraceptive 2 mg dienogest/30 µg ethinylestradiol (DNG/EE) is associated with a higher risk of venous thromboembolism (VTE) than the use of other combined oral low-dose contraceptives (i.e. containing ≤30 µg EE), particularly oral contraceptives containing levonorgestrel (LNG). The secondary objective was to investigate the VTE risk associated with drospirenone/ethinylestradiol (DRSP/EE) in comparison to low-dose LNG/EE.Methods This German community-based, case-control study recruited VTE cases from the primary care sector. Eligible cases were women aged 15-49 years with a VTE between January 2002 and February 2008. Four controls (women without a confirmed or potential VTE before the index date) were matched by age and region to each case. Medical information relevant for the assessment of VTE was abstracted from patient charts. Data on personal characteristics of the patients were collected via selfadministered questionnaires. At the end of the study a blinded adjudication of the reported VTE was conducted. Conditional logistic regression techniques were used, adjusting for nine potential confounders, including personal history of VTE, family history of VTE, body mass index, duration of current combined oral contraceptive (COC) use and smoking.

show abstract

“…6.2-16.6) per million woman-years. VTE mortality rate is significantly higher in current OC users than in controls under 25 years of age [33]. VTE presents as PE in nearly 50% of the cases, and PE is the most common cause of death in contraceptive users.…”

Section: Oral Contraception and The Risk Of Venous Thromboembolismmentioning

confidence: 94%

Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy

Rantanen¹,

Tatlısumak²

2013

Current Vascular Pharmacology

View full text Add to dashboard Cite

Stroke is a devastating disease affecting millions of people worldwide every year. Female stroke victims have higher mortality rates and they do not re-cover as well as men. Women's longevity and different vascular risk factor burden like a larger prevalence of atrial fibrillation play a role. Women also have unique risk factors such as oral contraception, pregnancy, estrogen decrease after the menopause and hormone replacement therapy, which should all be evaluated and taken into consideration in treatment decisions both in the acute phase of stroke and in secondary prevention. In this review, the evidence regarding these hormonal aspects and the risk of stroke in women are evaluated. The relevant guidelines are studied and research gaps identified. Future topics for research are recommended and current treatment possibilities and their risks discussed.

show abstract

Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives – an approach to specifying rates

Cited by 23 publications

References 21 publications

Risk Factors for Deep Vein Thrombosis in Women Aged 18 to 50: A Retrospective Analysis

Risk Factors for Deep Vein Thrombosis in Women Aged 18 to 50: A Retrospective Analysis

Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study

Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy

Contact Info

Product

Resources

About